TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven and inoperable advanced gastric adenocarcinoma.~2. Bi-dimensionally measurable disease by physical examination or image study (roentgenogram or computed tomography scan). The index lesions should be at least 20 mm × 10 mm in size.~3. Age must be older than 18 and younger than 75 year-old.~4. Karnofsky performance status\>60% (see Appendix)~5. Adequate bone marrow reserves, defined as white blood cell (WBC)\>4,000/l, absolute neutrophil count (ANC)\>1,500/l, platelet\>100,000/l.~6. Liver transaminases \<2.5 times upper normal limit if no liver metastasis and 5 times upper normal limit if liver metastasis is present; total bilirubin \<1.5 mg/dl; serum creatinine\<1.5mg/dl.~7. Serum triglyceride level\>70mg/dl.~8. Previous chemotherapy for metastatic disease is not allowed in this study. Previous adjuvant chemotherapy following curative gastrectomy is acceptable if the adjuvant chemotherapy has been completed for more than 6 months before enrollment into the present study.~9. Previous radiotherapy is allowed if the treatment was completed at least 4 weeks before the enrollment into this study.~10. Patients of childbearing age should have effective contraception during the study period.~11. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.~Exclusion Criteria:~1. Patients who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy.~2. Patients who refuse port-A catheter implantation.~3. Patients with brain or leptomeningeal metastases.~4. Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry.~5. Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy.~6. Life expectancy of less than 2 months.~7. Pregnant or nursing women may not participate. Women or men with reproductive potential may not participate unless they have agreed to use an effective contraceptive method.~8. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma in colon or rectum~* Age \>18~* Metastatic colorectal cancer progressed after chemotherapy regimens containing fluoropyrimidines, oxaliplatin and irinotecan.~* KRAS mutation in primary tumour or metastasis.~* Measurable disease according to RECIST~* ECOG performance status 0, 1 or 2~* Adequate function of liver, kidneys and bone marrow measured by biochemistry (max. 2 weeks before enrolment)~* EDTA clearance: Uncorrected GFR \> 45 ml/min.~* Neutrophilocytes ≥1.5 x 10\^9/l, leukocytes ≥3.0 x 10\^9/l, thrombocytes ≥100x10\^9/l~* ALAT ≤ 3 x upper normal value (ULN), bilirubin ≤ 3 x upper normal value, Aptt and INR normal (or 2-3 at AC treatment). (ALAT and basic phosphatase ≤ 5 x upper normal value in case of liver metastases).~* Blood samples and paraffin embedded tissue from primary tumour and/or metastases for translational research.~* Fertile men and women (women \<2 year after last menstruation) must use efficient birth control.~* Signed informed consent.~Exclusion Criteria:~* Clinically significant other concurrent disease making the patient unfit for participation in the study according to the investigator.~* Other malignant disease within 5 years prior to study enrolment, except from planocellular and basal cell carcinomas in the skin or carcinoma-in-situ cervix.~* Other experimental treatment within 30 days prior to treatment start.~* Pregnant or breastfeeding women.~* Clinical or radiological signs of CNS metastases.~* Planned radiation of target lesions.~* Concurrent vaccination against yellow fever.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation (tDCS) in Post-Stroke Working Memory Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of stroke and radiographically proven ischemic or hemorrhagic stroke (MRI required for ischemic stroke, CT sufficient for hemorrhagic stroke).~* Subject reports a decline in attention or short-term memory that began at the time of their stroke.~* Stroke occurred at least one month prior to first stimulation session.~* Ability to provide informed consent.~* Speak English (required for performing the cognitive tests)~Exclusion Criteria:~* Any other brain disease that can affect cognition (e.g., multiple sclerosis, dementia).~* Active mental illness such as depression or anxiety~* Large stroke involving cortex under the stimulation site (using subject provided CT or MRI).~* Currently taking any drugs that are sodium and/or calcium channel blockers not including amlodipine. This includes some seizure medications along with nicardipine, nifedipine, nimodipine, verapamil and diltiazem.~* Any history of epilepsy.~* Subject report of recent drug or alcohol abuse - within the past year.~* Subject report of pregnant or breastfeeding.~* Moderate to severe aphasia preventing subject from communicating fully.~* Any pacemakers, intracranial electrodes, implanted defibrillators, or any other electrical implants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tDCS conventional stimulation (Type: EXPERIMENTAL): Transcranial Direct Current Stimulation:~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes.
- High Definition (HD)-tDCS stimulation (Type: EXPERIMENTAL): Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes.
- tDCS sham stimulation (Type: SHAM_COMPARATOR): Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Evaluation of CML Patients in the National Compassionate Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CML Ph+ patients in chronic phase~* 18 years old or older~* Patients have received either Dasatinib or Nilotinib and resulted resistant or not tolerant to the drugs or have developed the T3151 mutation~* Patients have started Ponatinib at least 12 months before registration~* Informed consent signed at registration~Exclusion Criteria:~* CML Ph+ patients in accelerated or blast phase with acute lymphoblastic leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CML ph+ patients (Type: None): Chronic myeloid leukemia patients who are philadelphia positive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RSA vs. Nonop for 3 & 4-Part Proximal Humerus Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Displaced 3- and 4-part proximal humerus fractures.~* Age greater than or equal to 65 years old.~Exclusion Criteria~* Less than 65 years old.~* Medical comorbidities precluding surgical treatment or anesthesia~* Dementia or inability to provide adequate follow up.~* Pathologic fractures~* Open fractures~* Associated injuries: fracture dislocations, multiple or complex injuries of the ipsilateral limb, complete brachial plexopathy, vascular injury and polytrauma.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nonoperative Treatment (Type: OTHER): Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
- Operative Course for rTSA (Type: OTHER): Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Rehabilitation Program in Peripheral Facial Paralysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or women ≥ 18 years~* Diagnosed with UNILATERAL peripheral facial palsy according to the criteria of the International Classification of House and Brackmann (HB) between grades III and VI.~* Informed and having signed the consent form~* Patient who has a computer with webcam and an internet connection~* Affiliated to social security scheme (not accepted AME)~Exclusion Criteria:~* Major unable, protected, deprived of freedom~* Patients with facial palsy with a tumoral origin~* Patients with uncorrected vision problems~* Patient who have had botulinum toxin injections .~* Patient who have underwent rehabilitation of type electrical stimulations~* Patient who has a facial diplegia , a graft of the face or a grade I or II House and Brackmann (HB) .~* Patient who underwent rehabilitation of the paralyzed face

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: ACTIVE_COMPARATOR): Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
- Experimental Virtual Arm (Type: EXPERIMENTAL): Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of CPAP Machines With Reusable vs Disposable Circuits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants born at Ramaiah Medical College hospital ('inborn infants');~2. Infants born elsewhere, and admitted to Ramaiah Medical College hospital under 6 hours of age (outborn infants);~3. Infants with a gestational age at birth (weeks +days) in the range ≥ 28+0 to ≤ 36+6;~4. Infants thought to have RDS (clinically diagnosed after onset of respiratory distress \<6 hours of age, sometimes confirmed by X-ray showing homogenous bilateral opacity) who would routinely be provided CPAP therapy; and~5. Infants \<24 hours old at the time of fulfilling other inclusion criteria.~Exclusion Criteria:~1. Infants with a 1-minute Apgar score \<3 (as a marker of severe birth asphyxia);~2. Infants who received MV prior to randomisation;~3. Infants with suspected meconium aspiration syndrome will be excluded to avoid any imbalance in this condition across groups;~4. Infants clinically suspected to have another specified serious condition as their main disease process, diagnosed prior to randomisation, specifically: cardiac anomaly, other congenital malformation with respiratory sequelae, septicaemia, pulmonary haemorrhage, pneumothorax, meningitis, poor respiratory effort or recurrent apnoea, or brain haemorrhage (IVH Grades III or IV);~5. Infants who have an airway abnormality precluding the use of the standard CPAP interface proposed for this study (e.g., Pierre-Robin sequence, cleft lip or cleft palate) or who have a neuromuscular condition that interferes with respiration;~6. Any infant whose treating clinician believes should not be randomised due to some other condition, or for any other reason (reason to be documented).

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Dolphin CPAP (Type: EXPERIMENTAL): CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. \[Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement\]
- Fisher-Paykel CPAP (Type: ACTIVE_COMPARATOR): Fisher-Paykel (F\&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F\&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Controlled Study Evaluating Cryocontact Therapy of Infantile Hemangiomas of Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants \<=34 weeks GA with hemangioma~Exclusion Criteria:~* no hemangioma

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 11 Weeks
- Healthy Volunteers: f

Study Arms:
- Cryocontact therapy (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Social Health Games: The Use of Online Games to Decrease Loneliness in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Being 65 years or older~* Have access to a smartphone with an internet connection~Exclusion Criteria:~* Visual or cognitive impairments that limit independent use of a mobile phone~* Not being fluent in the Dutch language

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Social games (Type: EXPERIMENTAL): Participants in the social games group will be given access to an app with games that are either adaptations of well-known games or newly developed games, all designed to be played with just text messages and photos. A game is essentially a chat group with the people you invited to play that specific game with. Participants can play with their own network of family and friends, as well as other people in the same condition.
- Non-personal games (Type: ACTIVE_COMPARATOR): Participants in the active control group will be given access to an app that offers 'non-personal games'. The portal will contain a subset of the social games, which have been adapted for non-personal play. This means that all aspects that make the games personal are removed and discouraged. The games that remain can still be played with others (family/friends and others in the same condition), but are designed not to elicit personal interaction. Participants are asked to play the games at least twice a week, but may play as often as they like.
- Passive control (Type: NO_INTERVENTION): The passive control group will be given access to an app that contains no games. Similar to the other groups, the portal is used to complete the questionnaires. Use of other games, (gaming) apps or social media platforms is allowed in this group, as in the other groups. The only restriction they will not have access to the games offered in the social games and active control groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Detection in Glioma Excision

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged 18 years or above.~* Female patients are not pregnant at time of surgery.~* Patient has consented to craniotomy for suspected glioma of any type with 5-ALA infusion.~Exclusion Criteria:~• Participants are participating in another trial at time of operation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraoperative imaging of 5-ALA during tumour resection (Type: EXPERIMENTAL): Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged over 75 years~* Admission for a scheduled surgery (i.e. all oncologic digestive surgery , ureterostomy, nephrectomy or cystectomy, total hip or knee replacement)~* Participation agreement~Exclusion Criteria:~* Patients with a progressive and/or poorly managed psychiatric pathology (patients with stabilized depression could be included in the study)

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- multifaceted prevention program (Type: EXPERIMENTAL): None
- usual care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues